APLNR and neoplasm: The APLN/APLNR pathway is upregulated in malignant cells in many tumor types [174, 176, 177], as well as in tumor endothelial cells [178], and elevated Apelin levels are associated with disease progression and poor clinical outcome [176, 179–181].